WO1992016292A1 - Adsorption matrices - Google Patents

Adsorption matrices Download PDF

Info

Publication number
WO1992016292A1
WO1992016292A1 PCT/DK1992/000092 DK9200092W WO9216292A1 WO 1992016292 A1 WO1992016292 A1 WO 1992016292A1 DK 9200092 W DK9200092 W DK 9200092W WO 9216292 A1 WO9216292 A1 WO 9216292A1
Authority
WO
WIPO (PCT)
Prior art keywords
liquid
ligand
thiophilic
divinyl sulphone
lyotropic
Prior art date
Application number
PCT/DK1992/000092
Other languages
French (fr)
Inventor
Allan Otto Fog Lihme
Marie Bendix Hansen
Original Assignee
Kem-En-Tec A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kem-En-Tec A/S filed Critical Kem-En-Tec A/S
Priority to EP92907410A priority Critical patent/EP0639111A1/en
Priority to AU14688/92A priority patent/AU663700B2/en
Priority to JP4507119A priority patent/JPH06508058A/en
Publication of WO1992016292A1 publication Critical patent/WO1992016292A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206Organic carriers, supports or substrates
    • B01J20/3208Polymeric carriers, supports or substrates
    • B01J20/321Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206Organic carriers, supports or substrates
    • B01J20/3208Polymeric carriers, supports or substrates
    • B01J20/3212Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3214Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
    • B01J20/3217Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
    • B01J20/3219Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244Non-macromolecular compounds
    • B01J20/3246Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3251Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244Non-macromolecular compounds
    • B01J20/3246Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3253Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure not containing any of the heteroatoms nitrogen, oxygen or sulfur, e.g. aromatic structures
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30Processes for preparing, regenerating, or reactivating
    • B01J20/32Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244Non-macromolecular compounds
    • B01J20/3246Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3255Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. heterocyclic or heteroaromatic structures
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography

Definitions

  • the invention concerns novel thiophilic adsorption ma ⁇ trices, preferably for use in the isolation, purification 10 and immobilization of proteins from a liquid by salt- dependent adsorption chromatography, a process for produc ⁇ ing them, and a process for purifying protein, preferably immunoglobulin.
  • Salt-dependent adsorption chromatography comprises binding proteins to an adsorption matrix in the presence of high concentrations of salts, in particular lyotropic (water- structure forming) salts. Specific binding of proteins is achieved by adjusting the salt concentration, and the
  • bound proteins are eluted from the adsorption matrix by reducing the salt concentration in the medium.
  • Salt-dependent adsorption matrices are known, including e.g. metal chelate matrices, hydrophobic matrices and ma-
  • thiophilic adsorption matrices means hydrophilic adsorption matrices comprising a vinyl sul ⁇ phone group to which a ligand is covalently bound, said matrices being capable of adsorbing proteins, such as
  • Matrices exhibiting thiophilic adsorption are character ⁇ ized by binding proteins in another manner than hydropho ⁇ bic matrices. The differences are reflected i.a. in the fact that thiophilic matrices bind immunoglobulins from human serum much stronger than albumin at a given salt concentration. Albumin can be caused to bind to thiophilic matrices, but this typically requires a higher salt con ⁇ centration than is necessary for binding immunoglobulin. Hydrophobic matrices are characterized by binding albumin more strongly than immunoglobulin.
  • Thiophilic adsorption matrices are used in particular in the fractionation of biopolymers, such as nucleic acids, nucleotides, and proteins, including serum proteins, immunoglobulins and enzymes, and other polypeptides.
  • adsorption matrices having a distinct thio ⁇ philic nature are known, the so-called T-gels and the nitrilophoric matrices. Furthermore, thio-aromatic ma- trices having a hydrophobic nature are known.
  • thiophilic adsorption matrices which consist of hydrophilic matrices having covalently coupled chemical structures (ligands) of the type:
  • M is a polymeric hydrophilic network
  • X is an 0 (oxygen), N (nitrogen) or S (sulphur) atom
  • Y is an optionally substituted alkyl, aryl or hetero ⁇ aromatic group
  • S is a sulphur atom positioned two carbon atoms away from the sulphone group and belonging to the ligand.
  • a typical matrix belonging to this group is produced by reaction of mercapto ethanol with a divinyl sulphone acti ⁇ vated hydrophilic matrix (e.g. agarose):
  • M-0-CH 2 -CH 2 -S0 2 -CH CH 2 + HS-CH 2 ⁇ CH 2 -OH - M-0-CH 2 -CH 2 -S0 2 -CH 2 -CH 2 -S-CH 2 -CH 2 -OH
  • the thiophilic effect entails that these matrices do not bind albumin particularly effectively in contrast to known hydrophilic matrices which typically have long alkyl chains as ligands.
  • Thiophilic adsorption matrices of the above-mentioned type have surprisingly been found to have particular selecti ⁇ vity to immunoglobulins of the type IgG, IgA and IgM from serum and ascites liquids to which lyotropic salts, such as potassium sulphate have been added in a concentration of 0.5 M. After binding of immunoglobulin the matrix can be washed with an 0.5 M potassium sulphate buffer to remove non-bound contaminating proteins. The immuno ⁇ globulin can then be released by elution with a buffer with a low concentration of sodium chloride, e.g. 0.1 M sodium chloride.
  • This approach involves a rapid and convenient method of purifying immunoglobulins from liquids containing rela ⁇ tively high concentrations of immunoglobulin (above about 1 mg/ml), as is the case with e.g. serum and acites liquid.
  • thiophilic adsorption matrices of the above- mentioned type have a plurality of drawbacks associated with the exact chemical structure of the ligand.
  • a sulphur atom is included, positioned at a distance of two carbon atoms after a sulphone group.
  • this sulphur atom was considered essential to the quite special selectivity exhibited by the matrices, which appears from the EP Patent Specification 0 168 363 (example 4) and moreover from Jerker Porath and Makonnen Belew, Tibtech, 1987, vol. 5, p.
  • R is an aliphatic or heteromatic substituent com ⁇ prising at least one nitrile group
  • Y is preferably -CH 2 -CH 2 -S0 2 -CH 2 -CH 2 -
  • adsorbents have properties which are comparable with the thiophilic matrices described above, but they do not necessarily comprise the essential sulphur atom two carbon atoms terminally from the sulphone group. Presumably, this can be ascribed to the presence of one or more nitrile groups in the ligand.
  • Nitrilophoric adsorbents seem to have a limited use, it being known that nitriles can hydrolyze in aqueous solu ⁇ tions, in particular in basic or acid solutions, which means that the adsorbents are unstable under conditions which are typically used for regeneration, sterilisation and depyrogenization (typically at a high or low pH and autoclaving) between and during use for purification of immunoglobulins.
  • the thiophilic and nitrilophoric adsorbents described above have been used for purification of immunoglobulin from a liquid according to a process comprising the following steps: 1) an adsorption step in which the liquid, from which immunoglobulin is to be purified, is admixed with a solution of 0.5 M potassium sulphate + 0.1 M Tris/HCl with pH 7.6, following which the liquid is contacted with the adsorbent, typically by passing the liquid through a column containing the adsorbent,
  • Hutchens and Porath, Analytical Biochemistry, vol. 159, p. 217-226, 1986 describe the process as a general and op i- mal method of purifying immunoglobulins from serum
  • Belew, M et al., Journal of Immunological Methods, vol. 102, p. 173-182, 1987 describes such a process for purify ⁇ ing immunoglobulin from ascites liquid and in vitro cell culture supernatants containing monoclonal antibodies.
  • no processes have been taught for purify ⁇ ing immunoglobulins by using different pH and ion strength during adsorption and washing phase.
  • Lihme and Heegaard, Analytical Biochemistry, vol. 192, p. 64-69, 1991 describe the use of 0.75 M ammonium sulphate at neutral pH for purifying immunoglobulins from rabbit serum instead of 0.5 M potassium sulphate + 0.1 M Tris/HCl pH 7.6, as described above.
  • immunoglobu- lins e.g. lentillectin and trypsin, Hutchens and Porath
  • a drawback of the method is the provision of an eluate which, in addition to immunoglobulins, also con ⁇ tains significant amounts of contaminating proteins, such as e.g. transferrin and ⁇ -2-macroglobulin.
  • the process has a relatively low capacity for binding of immunoglobulins from liquids having a particularly low concentration of immunoglobulin, e.g. in vitro cell cul ⁇ ture supernatants which typically contain from 0.01 to 0.1 mg of immunoglobulin per ml.
  • the object of the present invention is to provide new al ⁇ ternative thiophilic adsorption matrices which are simple and inexpensive to produce, and which can be produced from divinyl sulphone activated matrices without special safety measures.
  • the invention provides a thiophilic nature of the adsorption matrix which is at least equal to the thiophilic nature of known thiophilic matrices, if the ligand has an aromatic or heteroaromatic nature and the S coupling atom between the divinyl sul- phone group and the ligand is replaced by 0 or N.
  • Particularly preferred ligands are selected from the sub- stituents stated in claim 2, the ligands stated in claim 3 being particularly preferred.
  • these ligand precursors are bound easily to the vinyl sulphone of a divinyl sulphone activated polymer network via oxygen or nitrogen belonging to the ligand. Furthermore, coupling of these precursors generally re ⁇ quires no special safety measures.
  • the ligand concentration may vary. Particularly preferred is a ligand concentration between 5 and 80 ⁇ moles/ml, pre ⁇ ferably between 5 and 40 ⁇ moles/ml, especially between 10 and 40 ⁇ moles/ml of wet matrix.
  • the hydrophilic network, to which the divinyl sulphone is bound may either be natural or synthetic organic polymers respectively selected from: polysaccharides, such as agar, agarose, dextran, starch and cellulose, and synthetic or- ganic polymers, such as polyacrylamide, polyamide, poly- imide, polyester, polyether and polymeric vinyl compounds, and substituted derivatives thereof either as particles, membranes or contained in membranes. Agarose is particu ⁇ larly preferred.
  • novel thiophilic adsorption matrices of the invention are relatively stable in aqueous solutions under strongly acid or strongly basic conditions and at high temperatures.
  • Another object of the present invention is to provide a process for producing thiophilic adsorption matrices according to the invention.
  • the polymer network is activated by being contacted with divinyl sulphone, following which the activated polymer network reacts with a ligand precursor.
  • the ligand precursor is selected from the group consisting of 2- hydroxypyridine, 4-hydroxypyridine, xanthine, 4-methoxy- phenol, 1-hydroxybenzotriazole, 4-aminobenzoic acid, 2- hydroxybenzylalcohol, 2,4-dihydroxy-6-methyl yridine, 4- aminosalicylic acid, 2-aminothiazole, 2-aminopyridine, 2- aminopyrimidine, 2-hydroxypyrimidine, 4-hydroxypyrimidine, imidazole, 3-amino-l,2,4-triazole, 4-hydroxybenzoic acid butyl amide, 2-hydroxybenzhydroxamic acid, phenol and 4- chlorophenol.
  • Another object of the invention is to provide a process for purifying protein from a liquid.
  • This object is achieved by providing a process for puri ⁇ fying protein from a liquid, wherein the liquid is con ⁇ tacted with a thiophilic adsorption matrix, and the pro- tein is then recovered from either the thiophilic adsorp ⁇ tion matrix or from the liquid, characterized in that the thiophilic adsorption matrix is a thiophilic adsorption matrix according to the invention.
  • Possible proteins according to the invention are all pro ⁇ teins, in particular serum proteins, including immunoglo ⁇ bulins, albumin, ⁇ -1-antitrypsin, orosomucoid, Gc-globu- lin, and factor VIII, proteins from fermented liquids, including streptavidin and 0-galactosidase, alkaline phosphatase from calf intestines, protein A and protein G.
  • serum proteins including immunoglo ⁇ bulins, albumin, ⁇ -1-antitrypsin, orosomucoid, Gc-globu- lin, and factor VIII
  • proteins from fermented liquids including streptavidin and 0-galactosidase, alkaline phosphatase from calf intestines, protein A and protein G.
  • Another object of the invention is to provide a process for purifying immunoglobulin from a liquid which gives a greater binding capacity than heretofore known methods by using both known thiophilic and nitrilophoric adsorption matrices and novel thiophilic matrices according to the invention.
  • the object is particularly to provide a process for purifying immunoglobulins from a liquid with a concen ⁇ tration of than less than 1 mg of immunoglobulin per ml of liquid, including in vitro cell culture supernatants con ⁇ taining (murine) immunoglobulins of the type IgG_, IgG.-,-. IgG 2B , IgG 3 , IgM and IgE.
  • This object is achieved by providing a process for purify ⁇ ing immunoglobulin, comprising adding a lyotropic buffer to the liquid, contacting the liquid with a thiophilic adsorption matrix, washing the thiophilic adsorption ma ⁇ trix with a lyotropic buffer solution, and eluting the washed thiophilic adsorption matrix with an elution li ⁇ quid, characterized in that the lyotropic buffer in the liquid has an ion strength above 2.25, preferably between 2.25 and 4.5, in particular between 3.0 and 4.0.
  • Another object of the invention is to provide a process giving a greater purity of the purified immunoglobulin than the known processes.
  • This object is achieved by providing a process for purify ⁇ ing immunoglobulin from a liquid, comprising adding a lyo ⁇ tropic buffer to the liquid, contacting the liquid with a thiophilic adsorption matrix, washing the thiophilic ad- sorption matrix with a lyotropic buffer solution, and eluting the washed thiophilic adsorption matrix with an elution liquid, characterized in that the lyotropic buffer solution has an ion strength below 2.25, preferably be ⁇ tween 0 and 2.25, in particular between 0.6 and 1.5.
  • pH in the lyotropic buffer solution is below 7.5, preferably between 2.5 and 7.5, in particular between 3.0 and 6.5, particularly pre ⁇ ferred being 3.5 to 6.0, especially 4.0 to 5.5.
  • the lyotropic buffer in the liquid has an ion strength above 2.25, preferably between 2.25 and 4.5, in particular between 3.0 and 4.0, thereby providing both a greater binding capacity and a greater purity than in the known methods.
  • the thiophilic matrix is selected from divinyl sulphone acti- vated polymer network, to which the divinyl sulphone groups are bound via an ether oxygen atom, a thioether sulphur atom or a nitrogen atom, the divinyl sulphone groups being moreover covalently bound to a ligand selected from:
  • an aromatic or heteroaromatic ring system which is optionally substituted, consisting of one or more rings whose substituents do not comprise nitile groups, and which is bound to a divinyl sulphone group via an oxygen atom or a nitrogen atom, and
  • a possible polymeric network for the known and novel thiophilic matrices of the invention is known poly ⁇ mer networks, such as polysaccharides, e.g.
  • agar agarose, dextran, starch and cellulose, in particular agarose, polyacrylamide, polyamide, polyimide, polyester, poly- ether, polymeric vinyl compounds and substituted deri ⁇ vatives thereof either as particles, membranes or con ⁇ tained in membranes.
  • Possible lyotropic salts for the lyotropic buffer and the lyotropic buffer solution according to the invention are known inorganic salts, such as sodium sulphate, potassium sulphate, ammonium sulphate, sodium phosphate, potassium phosphate and ammonium phosphate, or organic salts of polyvalent carboxylic acids, such as sodium citrate, so ⁇ dium tartrate, potassium citrate, potassium tartrate, or mixtures thereof.
  • Possible liquids according to the invention are immunoglo- bulin-containing liquids, in particular biological li ⁇ quids, such as blood, serum, ascites liquid or cell cul ⁇ ture supernatants, in particular cell culture super- natants.
  • Possible immunoglobulins according to the invention are all immunoglobulins, in particular immunoglobulins of the type IgG. ⁇ IgG 2A , IgG 2B , IgGg, IgA, IgM, IgD and IgE and in particular murine and human immunoglobulins.
  • the thiophilic matrices are not only useful for binding and purifying im ⁇ vunoglobu- lins, but they can also be used for binding other pro ⁇ teins, such as other serum proteins than immunoglobulins, depending upon the used concentration of lyotropic salts in the sample (Lihme & Heegaard, Analytical Biochemistry, vol. 192, p. 64-69, 1991). In this case too it will be advantageous with a smaller concentration of salts in the sample.
  • the known process for purifying immunoglo ⁇ bulins by means of thiophilic or nitrilophoric matrices is restricted i.a. because the binding capacity for immuno ⁇ globulin from liquids with very low concentrations of immunoglobulin (i.e. below about 1 mg/ml) is relatively low under known binding conditions (0.5 M potassium sul ⁇ phate or 0.75 M ammonium sulphate).
  • the low immunoglobulin concentration typically occurs with the cell culture supernatants resulting from the production of monoclonal antibodies by in vitro cultivation of hybridoma cells, in contrast to serum and ascites liquids which contain a much higher concentration of immunoglobulin.
  • the binding capacity for immunoglobulin to adsorption matrices having a thiophilic nature increases steeply with increasing ion strength (concentration) of the known lyotropic salts in the liquid from which the immunoglobulin is to be purified.
  • the salts capable of contributing to binding immunoglobu ⁇ lin to thiophilic and nitrilophoric adsorption matrices belong to the group of lyotropic (water structure forming) salts. Examples of such are salts containing sulphate or phosphate ions typically with sodium, potassium or ammo- nium ions as counter ions. Furthermore, some organic ions also have lyotropic activity, e.g. the multivalent anions of organic polyvalent carboxylic acids (e.g. citrate or tartrate ions).
  • provision of an increased binding ca- pacity by increasing the ion strength over the ion strength used in the prior art is not limited to ammonium sulphate, but that the increased binding capacity achiev ⁇ able applies to all inorganic and organic salts having lyotropic properties.
  • the process of the invention may e.g. be used in the puri ⁇ fication of immunoglobulin from monoclonal in vitro cell culture supernatants according to the following specific procedure, comprising:
  • eluting the bound proteins, including immunoglobulins with a buffer solution, which has a low salt content, e.g. 0.05 M Tris/HCl, pH 9.0.
  • the process of the invention may also be used for purify- ing immunoglobulins from other liquids, e.g. serum or ascites liquid, but then requires individual adjustment of the ion strength of the flushing buffer with respect to the lyotropic salt and the pH value of the flushing buffer.
  • the result will be an increased purity of the immunoglobulin, without the binding capacity of the ad ⁇ sorption matrix being significantly diminished.
  • individual adjustment of ion strength and pH value will be desirable depending upon the type of the immunoglobulin (for murine antibodies depending upon whether IgG-, IgG 2A - IgG 2B , I G , IgM or IgE is involved).
  • the preferred ion strength of the flushing buffer depends upon the specific application and the present contamina ⁇ tions, but is typically between 0 and 2.25. In most cases the most preferred range is between 0.6 and 1.5.
  • the preferred pH value of the flushing buffer depends upon the specific application, but is typically between pH 2.5 and pH 7.5. Owing to the stability of the immunoglobulin during the flushing procedure and the efficiency of the process, a more preferred range will be between pH 3.0 and pH 6.5, while the most preferred range will be between pH 3.5 and pH 6.0. It is particularly pre ⁇ ferred that pH is between 4.0 and 5.5.
  • the pH value of the elution buffer is preferably above 7.0, but may also be lower. Elution can also be performed by changing the dielectric!ty constant of the buffer, e.g. by addition of ethylene glycol.
  • the selection of elution method is generally independent upon the process for bind ⁇ ing the immunoglobulin and subsequent washing of contami- nations.
  • the resulting matrix contained about 40 micromoles of 2- hydroxypyrine per ml of wet drained matrix.
  • the resulting matrix contained about 40 micromoles of 4- hydroxypyrine per ml of wet drained matrix.
  • the resulting matrix contained about 40 micromoles of 4- methoxyphenol per ml of wet drained matrix.
  • the resulting matrix contained about 40 micromoles of 4- aminobenzoic acid per ml of wet drained matrix.
  • the resulting matrix contained about 40 micromoles of phe ⁇ nol per ml of wet drained matrix.
  • the resulting matrices contained about 30-40 micromoles of ligands.
  • the resulting matrix contained about 20 micromoles of phe ⁇ nol per ml of wet drained matrix.
  • the resulting matrix contained about 5 micromoles of phe- nol per ml of wet drained matrix.
  • the gel was incubated with the solution for 18 hours at room temperature.
  • the resulting matrix contained about 40 micromoles of mer ⁇ capto ethanol per ml of wet drained matrix.
  • the matrices which were produced according to examples 1- 4 and example 8, were used for purifying immunoglobulins from human serum according to the following known process (Lihme & Heegaard, Analytical Biochemistry, vol. 192, p. 64-69, 1991):
  • the EU figure of the eluate was calculated by means of the following formula:
  • the matrices of the invention and the known matrix thus bound comparable amounts of total protein and substantially the same amounts of immunoglobu ⁇ lin. None of the matrices bound albumin. The smaller amount of total protein eluted from the 4-hydroxypyridine matrix reflects a higher selectivity for immunoglobulin than the other matrices. It can therefore be concluded that the position of the substituent and on the whole the fine structure of the ligand have a decisive influence on the selectivity of the matrix.
  • the raw material was human serum, and purification was performed so that the conditions during application pro- mote binding of most serum proteins, (i.e. a higher ammo ⁇ nium sulphate concentration was used than the one used for selective binding of immunoglobulins) .
  • the matrices were eluted with a gradient from 0.01 M K 2 HP0 4 , 1.5 M (NH 4 ) 2 S0 4 pH 7.2 to 0.01 M K 2 HP0 4 , 0.25 M NaCl pH 7.2.
  • the eluates were collected in fractions and analyzed by fused rocket immunoelectrophoresis for qualitative deter ⁇ mination of the protein content.
  • the adsorption matrix with the highest content of phenyl groups (40 micromoles/ml) bound the proteins most strongly, i.e. the proteins were gene ⁇ rally eluted at a lower ion strength compared with the two other adsorption matrices.
  • this matrix also bound the proteins more strongly than known thiophilic matrices, such as the mercapto ethanol derivative, the immunoglobulin G bound so strongly that it could only be liberated by a subsequent elution with 40% ethylene gly- col.
  • the thiophilic nature showed itself clearly in that albumin bound much more weakly to the matrix than immunoglobulin and much more weakly than the known hydro- phobic matrices, such as octyl-Sepharose.
  • the adsorption matrix with a content of about 20 micro ⁇ moles of phenyl groups per ml of wet gel, exhibited a binding pattern which corresponds closely to the pattern achieved with known thiophilic matrices with a higher ligand concentration (about 40-60 micromoles/ml).
  • the adsorption matrix with a content of about 5 micro ⁇ moles of phenyl groups per ml, bound the proteins rather weakly, but still exhibited preference to binding of immunoglobulins.
  • the test is performed like process I, but the potassium sulphate added in item 1 is replaced by 0.8 M ammonium sulphate, pH being kept constant at 7.6.
  • the test is performed like process II, the ammonium sul- phate concentration being merely increased to 1.0 M.
  • the test is performed like process II, the ammonium sul- phate concentration being merely increased to 1.2 M.
  • results are expressed as number of ml cell culture supernatant passing the column with the adsorption matrix before the effluent concentration of murine immunoglobulin is 50% of the start concentration (defined as "50% satura ⁇ tion” ).
  • Process III >300 Process IV >300
  • an increase in the ion strength also has a strong positive effect on the binding capacity when us ⁇ ing sodium sulphate instead of ammonium sulphate.
  • the eluate was collected in one fraction and analyzed for purity by means of sodiumdodecyl polyacrylamide electrophoresis followed by electronic scanning.
  • the yield in mg of murine immunoglobulin G. is determined by quantitative rocket immunoelectrophoresis.
  • the purity is the immunoglobulin in % of the total amount of protein in the sample.
  • the test was performed like process I, the washing buffer in item 3 being merely replaced by 0.3 M ammonium sulphate + 0.05 M sodium acetate, pH 5.2.
  • Process I 11.5 about 30 Process II 11.0 90 Process III ⁇ 0.5 95

Abstract

New thiophilic adsorption matrices comprising a hydrophilic polymer network to which divinyl sulphone groups are bound via an ether oxygen atom, or thioether sulphur atom or a nitrogen atom, and the divinyl sulphone groups are moreover bound to a ligand, which is an aromatic or heteroaromatic ring system consisting of one or more rings, which are optionally substituted, but do not comprise nitrile groups; a process for producing them, and a process for purifying immunoglobulin from a liquid using thiophilic adsorption matrices.

Description

Adsorption Matrices
1. BACKGROUND OF THE INVENTION f 5
The Technical Field
The invention concerns novel thiophilic adsorption ma¬ trices, preferably for use in the isolation, purification 10 and immobilization of proteins from a liquid by salt- dependent adsorption chromatography, a process for produc¬ ing them, and a process for purifying protein, preferably immunoglobulin.
15 Salt-dependent adsorption chromatography comprises binding proteins to an adsorption matrix in the presence of high concentrations of salts, in particular lyotropic (water- structure forming) salts. Specific binding of proteins is achieved by adjusting the salt concentration, and the
20 bound proteins are eluted from the adsorption matrix by reducing the salt concentration in the medium.
Salt-dependent adsorption matrices are known, including e.g. metal chelate matrices, hydrophobic matrices and ma-
25 trices of thiophilic nature. In the present specification the designation "thiophilic adsorption matrices" means hydrophilic adsorption matrices comprising a vinyl sul¬ phone group to which a ligand is covalently bound, said matrices being capable of adsorbing proteins, such as
30 serum proteins in the presence of high concentrations of lyotropic salts, such as alkali sulphates and alkali phos¬ phates. This particularly distinct thiophilic adsorption
I
. nature is primarily believed to be caused by the sulphur atom in the divinyl sulphone group, to which should be 35 added that the degree of thiophilic nature can be intensi¬ fied or weakened by the ligand bound thereto. Matrices exhibiting thiophilic adsorption are character¬ ized by binding proteins in another manner than hydropho¬ bic matrices. The differences are reflected i.a. in the fact that thiophilic matrices bind immunoglobulins from human serum much stronger than albumin at a given salt concentration. Albumin can be caused to bind to thiophilic matrices, but this typically requires a higher salt con¬ centration than is necessary for binding immunoglobulin. Hydrophobic matrices are characterized by binding albumin more strongly than immunoglobulin.
Thiophilic adsorption matrices are used in particular in the fractionation of biopolymers, such as nucleic acids, nucleotides, and proteins, including serum proteins, immunoglobulins and enzymes, and other polypeptides.
Two types of adsorption matrices having a distinct thio¬ philic nature are known, the so-called T-gels and the nitrilophoric matrices. Furthermore, thio-aromatic ma- trices having a hydrophobic nature are known.
Prior Art
The US Patent Specification 4 696 980 describes thiophilic adsorption matrices which consist of hydrophilic matrices having covalently coupled chemical structures (ligands) of the type:
M-X-CH2CH2S02CH-,CH2-S-Y,
wherein M is a polymeric hydrophilic network,
X is an 0 (oxygen), N (nitrogen) or S (sulphur) atom,
Y is an optionally substituted alkyl, aryl or hetero¬ aromatic group, and S is a sulphur atom positioned two carbon atoms away from the sulphone group and belonging to the ligand.
A typical matrix belonging to this group is produced by reaction of mercapto ethanol with a divinyl sulphone acti¬ vated hydrophilic matrix (e.g. agarose):
First a hydrophilic matrix M-OH is activated with divinyl sulphone:
M-OH + CH2=CH-S02-CH=CH2 - M-0-CH2-CH2-S02-CH=O_2
then the divinyl sulphone activated hydrophilic matrix is reacted with mercapto ethanol:
M-0-CH2-CH2-S02-CH=CH2 + HS-CH2~CH2-OH - M-0-CH2-CH2-S02-CH2-CH2-S-CH2-CH2-OH
The thiophilic effect entails that these matrices do not bind albumin particularly effectively in contrast to known hydrophilic matrices which typically have long alkyl chains as ligands.
Thiophilic adsorption matrices of the above-mentioned type have surprisingly been found to have particular selecti¬ vity to immunoglobulins of the type IgG, IgA and IgM from serum and ascites liquids to which lyotropic salts, such as potassium sulphate have been added in a concentration of 0.5 M. After binding of immunoglobulin the matrix can be washed with an 0.5 M potassium sulphate buffer to remove non-bound contaminating proteins. The immuno¬ globulin can then be released by elution with a buffer with a low concentration of sodium chloride, e.g. 0.1 M sodium chloride. This approach involves a rapid and convenient method of purifying immunoglobulins from liquids containing rela¬ tively high concentrations of immunoglobulin (above about 1 mg/ml), as is the case with e.g. serum and acites liquid.
However, thiophilic adsorption matrices of the above- mentioned type have a plurality of drawbacks associated with the exact chemical structure of the ligand.
As appears from the above chemical structure of thiophilic adsorption matrices, a sulphur atom is included, positioned at a distance of two carbon atoms after a sulphone group. In the past, this sulphur atom was considered essential to the quite special selectivity exhibited by the matrices, which appears from the EP Patent Specification 0 168 363 (example 4) and moreover from Jerker Porath and Makonnen Belew, Tibtech, 1987, vol. 5, p. 225-229, in particular page 226, where it is con- eluded that if the sulphur atom is replaced by nitrogen or oxygen the "thiophilic" nature will be much weaker, it being reported to decline through the series: S > N >> 0,Se. This teaching suggests a strong restriction in the selection of possible and available substances that can be coupled to the divinyl sulphone activated matrix with the consequent desired effect. In addition, many thiol com¬ pounds, e.g. mercapto ethanol, are toxic and malodorous, and it is therefore strenuous to work with these because of the necessary safety measures which are to be taken in the coupling of the substance to the actived matrix. This applies in particular in case of a situation of use where the toxicity of the activation reagent, divinyl sulphone, has not been taken into account beforehand, which occurs e.g. if the activated matrix has been produced at an earlier time. The US Patent Specification 3 897 467 describes nitrilo- phoric adsorbents comprising a hydrophilic polymer coupled with a ligand of the structure:
M-Y-X-R,
wherein R is an aliphatic or heteromatic substituent com¬ prising at least one nitrile group,
X is NQ, S or 0, wherein Q is H(CH Jit)II with n = 0,1,2 or 3 and
Y is preferably -CH2-CH2-S02-CH2-CH2-
These adsorbents have properties which are comparable with the thiophilic matrices described above, but they do not necessarily comprise the essential sulphur atom two carbon atoms terminally from the sulphone group. Presumably, this can be ascribed to the presence of one or more nitrile groups in the ligand.
Nitrilophoric adsorbents seem to have a limited use, it being known that nitriles can hydrolyze in aqueous solu¬ tions, in particular in basic or acid solutions, which means that the adsorbents are unstable under conditions which are typically used for regeneration, sterilisation and depyrogenization (typically at a high or low pH and autoclaving) between and during use for purification of immunoglobulins.
The thiophilic and nitrilophoric adsorbents described above have been used for purification of immunoglobulin from a liquid according to a process comprising the following steps: 1) an adsorption step in which the liquid, from which immunoglobulin is to be purified, is admixed with a solution of 0.5 M potassium sulphate + 0.1 M Tris/HCl with pH 7.6, following which the liquid is contacted with the adsorbent, typically by passing the liquid through a column containing the adsorbent,
2) a washing step in which non-bound proteins are washed out of the adsorbent with a buffer solution containing 0.5 M potassium sulphate + 0.1 M Tris/HCl with pH 7.6, and
3) an elution step in which the bound proteins, includ¬ ing the immunoglobulins, are eluted from the adsor- bent with a buffer solution having a low salt con¬ tent, e.g. 0.05 M sodium phosphate with pH 8.0.
Hutchens and Porath, Analytical Biochemistry, vol. 159, p. 217-226, 1986 describe the process as a general and op i- mal method of purifying immunoglobulins from serum, and Belew, M et al., Journal of Immunological Methods, vol. 102, p. 173-182, 1987 describes such a process for purify¬ ing immunoglobulin from ascites liquid and in vitro cell culture supernatants containing monoclonal antibodies. As far as is known, no processes have been taught for purify¬ ing immunoglobulins by using different pH and ion strength during adsorption and washing phase. Lihme and Heegaard, Analytical Biochemistry, vol. 192, p. 64-69, 1991 describe the use of 0.75 M ammonium sulphate at neutral pH for purifying immunoglobulins from rabbit serum instead of 0.5 M potassium sulphate + 0.1 M Tris/HCl pH 7.6, as described above.
It is moreover known that other proteins than immunoglobu- lins, e.g. lentillectin and trypsin, Hutchens and Porath,
Analytical Biochemistry, vol. 159, p, 217-226, 1986, and serum albumin, Lihme and Heegaard, Analytical Biochemi¬ stry, vol. 192, p. 64-69, 1991 can be bound to thiophilic adsorbents if the ion strength is increased beyond what corresponds to 0.5 M potassium sulphate (I = 1.5). It is thus known that binding of serum albumin can take place at an ammonium sulphate concentration of about 1.2 M (I = 3.6), Lihme and Heegaard, Analytical Biochemistry, vol. 192, p. 64-69, 1991.
However, a drawback of the method is the provision of an eluate which, in addition to immunoglobulins, also con¬ tains significant amounts of contaminating proteins, such as e.g. transferrin and α-2-macroglobulin. Furthermore, the process has a relatively low capacity for binding of immunoglobulins from liquids having a particularly low concentration of immunoglobulin, e.g. in vitro cell cul¬ ture supernatants which typically contain from 0.01 to 0.1 mg of immunoglobulin per ml.
These drawbacks limit the use of the separation principle and entail that it will often be necessary to combine the method with other supplementary purification steps, which both reduces the yield and adds to the costs.
2. DISCLOSURE OF THE INVENTION
The object of the present invention is to provide new al¬ ternative thiophilic adsorption matrices which are simple and inexpensive to produce, and which can be produced from divinyl sulphone activated matrices without special safety measures.
This object is achieved according to the invention by pro¬ viding a thiophilic adsorption matrix comprising a hydro- philic polymer network to which divinyl sulphone groups are bound via an ether oxygen atom, a thioether sulphur atom or a nitrogen atom, and the divinyl sulphone groups are moreover covalently bound to a ligand, characterized in that the ligand is a group of the general formula X-R, wherein X is NQ, wherein N is nitrogen, Q is H(CH -„b)I and n = 0,1,2 or 3, or O (oxygen), and wherein R is an aromatic or heteroaromatic ring system which is optionally substituted, consisting of one or more rings, and R does not comprise nitrile groups.
It has surprisingly been found that the invention provides a thiophilic nature of the adsorption matrix which is at least equal to the thiophilic nature of known thiophilic matrices, if the ligand has an aromatic or heteroaromatic nature and the S coupling atom between the divinyl sul- phone group and the ligand is replaced by 0 or N.
It is thus surprising that the reduced thiophilic nature of the adsorption matrix according to the prior art (Porath & Belew, ibid. ) does not apply to the adsorption matrix of the invention.
Particularly preferred ligands are selected from the sub- stituents stated in claim 2, the ligands stated in claim 3 being particularly preferred. In addition to being inexpensive, these ligand precursors are bound easily to the vinyl sulphone of a divinyl sulphone activated polymer network via oxygen or nitrogen belonging to the ligand. Furthermore, coupling of these precursors generally re¬ quires no special safety measures.
The ligand concentration may vary. Particularly preferred is a ligand concentration between 5 and 80 μmoles/ml, pre¬ ferably between 5 and 40 μmoles/ml, especially between 10 and 40 μmoles/ml of wet matrix. The hydrophilic network, to which the divinyl sulphone is bound, may either be natural or synthetic organic polymers respectively selected from: polysaccharides, such as agar, agarose, dextran, starch and cellulose, and synthetic or- ganic polymers, such as polyacrylamide, polyamide, poly- imide, polyester, polyether and polymeric vinyl compounds, and substituted derivatives thereof either as particles, membranes or contained in membranes. Agarose is particu¬ larly preferred.
In addition to being simple and inexpensive to produce, and without having to be produced under special safety measures, the novel thiophilic adsorption matrices of the invention are relatively stable in aqueous solutions under strongly acid or strongly basic conditions and at high temperatures.
Another object of the present invention is to provide a process for producing thiophilic adsorption matrices according to the invention. These thiophilic adsorption matrices comprise a hydrophilic polymer network to which divinyl sulphone groups are bound via an ether oxygen atom, a thioether sulphur atom or a nitrogen atom, and the divinyl sulphone groups are moreover covalently bound to a ligand, said ligand being a group of the general formula X-R, wherein X is NQ, wherein N is nitrogen and Q is H(CH->) and n = 0,1,2,3 or 0 (oxygen), and wherein R is an aromatic or heteroaromatic ring system which is optionally substituted, consisting of one or more rings, and R does not comprise nitrile groups.
The polymer network is activated by being contacted with divinyl sulphone, following which the activated polymer network reacts with a ligand precursor. The ligand precursor is selected from the group consisting of 2- hydroxypyridine, 4-hydroxypyridine, xanthine, 4-methoxy- phenol, 1-hydroxybenzotriazole, 4-aminobenzoic acid, 2- hydroxybenzylalcohol, 2,4-dihydroxy-6-methyl yridine, 4- aminosalicylic acid, 2-aminothiazole, 2-aminopyridine, 2- aminopyrimidine, 2-hydroxypyrimidine, 4-hydroxypyrimidine, imidazole, 3-amino-l,2,4-triazole, 4-hydroxybenzoic acid butyl amide, 2-hydroxybenzhydroxamic acid, phenol and 4- chlorophenol.
Another object of the invention is to provide a process for purifying protein from a liquid.
This object is achieved by providing a process for puri¬ fying protein from a liquid, wherein the liquid is con¬ tacted with a thiophilic adsorption matrix, and the pro- tein is then recovered from either the thiophilic adsorp¬ tion matrix or from the liquid, characterized in that the thiophilic adsorption matrix is a thiophilic adsorption matrix according to the invention.
Possible proteins according to the invention are all pro¬ teins, in particular serum proteins, including immunoglo¬ bulins, albumin, α-1-antitrypsin, orosomucoid, Gc-globu- lin, and factor VIII, proteins from fermented liquids, including streptavidin and 0-galactosidase, alkaline phosphatase from calf intestines, protein A and protein G.
Another object of the invention is to provide a process for purifying immunoglobulin from a liquid which gives a greater binding capacity than heretofore known methods by using both known thiophilic and nitrilophoric adsorption matrices and novel thiophilic matrices according to the invention. The object is particularly to provide a process for purifying immunoglobulins from a liquid with a concen¬ tration of than less than 1 mg of immunoglobulin per ml of liquid, including in vitro cell culture supernatants con¬ taining (murine) immunoglobulins of the type IgG_, IgG.-,-. IgG2B, IgG3, IgM and IgE.
This object is achieved by providing a process for purify¬ ing immunoglobulin, comprising adding a lyotropic buffer to the liquid, contacting the liquid with a thiophilic adsorption matrix, washing the thiophilic adsorption ma¬ trix with a lyotropic buffer solution, and eluting the washed thiophilic adsorption matrix with an elution li¬ quid, characterized in that the lyotropic buffer in the liquid has an ion strength above 2.25, preferably between 2.25 and 4.5, in particular between 3.0 and 4.0.
It has surprisingly been found that an ion strength above 2.25 can result in a considerably greater capacity than the one achievable by known methods.
Another object of the invention is to provide a process giving a greater purity of the purified immunoglobulin than the known processes.
This object is achieved by providing a process for purify¬ ing immunoglobulin from a liquid, comprising adding a lyo¬ tropic buffer to the liquid, contacting the liquid with a thiophilic adsorption matrix, washing the thiophilic ad- sorption matrix with a lyotropic buffer solution, and eluting the washed thiophilic adsorption matrix with an elution liquid, characterized in that the lyotropic buffer solution has an ion strength below 2.25, preferably be¬ tween 0 and 2.25, in particular between 0.6 and 1.5.
It has surprisingly been found that the low ion strength gives a greater purity of the eluted immunoglobulin, without this resulting in a smaller yield of the immuno¬ globulin. In a particularly preferred embodiment pH in the lyotropic buffer solution is below 7.5, preferably between 2.5 and 7.5, in particular between 3.0 and 6.5, particularly pre¬ ferred being 3.5 to 6.0, especially 4.0 to 5.5.
In another preferred embodiment the lyotropic buffer in the liquid has an ion strength above 2.25, preferably between 2.25 and 4.5, in particular between 3.0 and 4.0, thereby providing both a greater binding capacity and a greater purity than in the known methods.
Possible thiophilic adsorption matrices are known as well as novel thiophilic matrices of the invention. Thus, the thiophilic matrix is selected from divinyl sulphone acti- vated polymer network, to which the divinyl sulphone groups are bound via an ether oxygen atom, a thioether sulphur atom or a nitrogen atom, the divinyl sulphone groups being moreover covalently bound to a ligand selected from:
a) an alkyl, aryl or heteroaromatic group which is op¬ tionally substituted, and which is bound to a divinyl sulphone group via a sulphur atom,
b) an aromatic or heteroaromatic ring system, which is optionally substituted, consisting of one or more rings whose substituents do not comprise nitile groups, and which is bound to a divinyl sulphone group via an oxygen atom or a nitrogen atom, and
c) an aliphatic or a heterocyclic ring system having at least one nitrogen atom in the ring with one or more side groups consisting of or comprising nitrile groups, bound to a divinyl sulphone group via a sulphur atom, an oxygen atom or a nitrogen atom. Moreover, a possible polymeric network for the known and novel thiophilic matrices of the invention is known poly¬ mer networks, such as polysaccharides, e.g. agar, agarose, dextran, starch and cellulose, in particular agarose, polyacrylamide, polyamide, polyimide, polyester, poly- ether, polymeric vinyl compounds and substituted deri¬ vatives thereof either as particles, membranes or con¬ tained in membranes.
Possible lyotropic salts for the lyotropic buffer and the lyotropic buffer solution according to the invention are known inorganic salts, such as sodium sulphate, potassium sulphate, ammonium sulphate, sodium phosphate, potassium phosphate and ammonium phosphate, or organic salts of polyvalent carboxylic acids, such as sodium citrate, so¬ dium tartrate, potassium citrate, potassium tartrate, or mixtures thereof.
Possible liquids according to the invention are immunoglo- bulin-containing liquids, in particular biological li¬ quids, such as blood, serum, ascites liquid or cell cul¬ ture supernatants, in particular cell culture super- natants.
Possible immunoglobulins according to the invention are all immunoglobulins, in particular immunoglobulins of the type IgG.^ IgG2A, IgG2B, IgGg, IgA, IgM, IgD and IgE and in particular murine and human immunoglobulins.
3. DETAILED DESCRIPTION
Thiophilic adsorption matrices
As mentioned, it has surprisingly been found that the replacement of the said sulphur atom by e.g. oxygen or nitrogen resulting in a reduced thiophilic efficiency according to the prior art, unless Y contains one or more nitrile groups, does not apply if the ligand has an aro¬ matic or heteroaromatic nature. In contrast, it has been found that matrices in which e.g. -S-R has been replaced by a phenyl ring, i.e. matrices having the structural formula:
M-X-CH2CH2S02CH2CH2-0-C6H_.,
exhibit a particularly strong thiophilic binding, which is even stronger than the binding that can be achieved with the corresponding mercapto ethanol derivative according to the prior art. The characteristic thiophilic interaction of this phenyl derivatised matrix manifests itself in that human serum immunoglobulin G binds more strongly to the matrix than albumin. The stronger thiophilic binding of this matrix, compared with the mercapto ethanol deriva¬ tive, manifests itself in that human immunoglobulin G is bound more effectively at lower concentrations of lyotro- pic salts in the sample. This is an effect which greatly depends upon the ligand concentration on the matrix, ma¬ trices with a high ligand concentration binding the immunoglobulin even in the absence of lyotropic salts, while matrices with a low or average ligand concentration require the presence of lyotropic salts to bind effec¬ tively. This stronger thiophilic binding of the immunoglo¬ bulin at high ligand concentrations may be desirable and advantageous in certain cases; e.g. in industrial applica¬ tions where large amounts of liquid containing salts, such as ammonium sulphate or potassium sulphate, may pose a problem in terms of contamination.
It should moreover be noted that the thiophilic matrices are not only useful for binding and purifying imπvunoglobu- lins, but they can also be used for binding other pro¬ teins, such as other serum proteins than immunoglobulins, depending upon the used concentration of lyotropic salts in the sample (Lihme & Heegaard, Analytical Biochemistry, vol. 192, p. 64-69, 1991). In this case too it will be advantageous with a smaller concentration of salts in the sample.
It is thus new and surprising that phenol coupled to di¬ vinyl sulphone activated agarose has a thiophilic nature in its protein adsorbing manner.
In a study of a plurality of different ligands containing an aromatic or heteroaromatic core with or without sub- stituents, it has moreover been found that the sulphur atom can generally be replaced by oxygen or nitrogen while maintaining the thiophilic nature if Y has an aromatic or heteroaromatic nature. The following substances were coupled to divinyl sulphone activated agarose:
2-hydroxypyridine, 4-hydroxypyridine, xanthine, 4-methoxy- phenol, 1-hydroxybenzotriazole, 4-aminobenzoic acid, 2- hydroxybenzylalcohol, 2,4-dihydroxy-6-methylpyrimidine, 4- aminosalicylic acid, 2-aminothiazole, 2-aminopyridine, 2- aminepyrimidine, 2-hydroxypyrimidine, 4-hydroxypyrimidine, imidazole, 3-amino-l,2,4-triazole, 4-hydroxybenzoic acid butyl amide, 2-hydroxybenzhydroxamic acid, phenol and 4- chlorophenol. They all provided an adsorption matrix hav¬ ing a strong thiophilic nature.
It is common to the studied ligands that none of the re- suiting adsorption matrices bind albumin noticeably, while they all bind immunoglobulins of the type IgG, IgA and IgM extremely effectively and at least just as effectively as known adsorption matrices based on mercapto ethanol deri¬ vatives. In addition to binding immunoglobulins strongly, it has been found that the various adsorption matrices exhibit small, but distinct differences in selectivity to binding of other proteins. For purification of specific proteins it is therefore important that the substitutents on the aromatic or heteroaromatic core are selected such as to provide the best possible capacity and purity. Thus, by routine tests a skilled person can select the ligand most suitable for a specific protein.
It has additionally also been found that various isomers of the same substance can exhibit great differences in binding strength as well as in selectivity. This is illu¬ strated by coupling of 2-hydroxypyridine and 4-hydroxy- pyridine (examples 1 and 2), respectively, the 2- hydroxypyridine derivative binding significantly more protein than the 4-hydroxypyridine derivative. It is common to both derivatives that they do not bind albumin, or that the binding of albumin is very weak.
Purification of immunoglobulin
As mentioned, the known process for purifying immunoglo¬ bulins by means of thiophilic or nitrilophoric matrices is restricted i.a. because the binding capacity for immuno¬ globulin from liquids with very low concentrations of immunoglobulin (i.e. below about 1 mg/ml) is relatively low under known binding conditions (0.5 M potassium sul¬ phate or 0.75 M ammonium sulphate). The low immunoglobulin concentration typically occurs with the cell culture supernatants resulting from the production of monoclonal antibodies by in vitro cultivation of hybridoma cells, in contrast to serum and ascites liquids which contain a much higher concentration of immunoglobulin. However, it has surprisingly been found that the binding capacity for immunoglobulin to adsorption matrices having a thiophilic nature (including the known thiophilic and nitrilophoric as well as the new thiophilic matrices of the invention) increases steeply with increasing ion strength (concentration) of the known lyotropic salts in the liquid from which the immunoglobulin is to be purified.
It has thus been found that binding of monoclonal antibody from in vitro cell culture supernatants was strongly in¬ tensified by an increase of the ion strength in the liquid during the binding process, from 2.25 to 3.0 (correspond¬ ing to an increase in the ammonium sulphate concentration in the liquid from 0.75 M to 1 M). This increased binding strength results in a corresponding increase in the total binding capacity of 300-1000%. A comparison between 0.5 M potassium sulphate (ion strength = 1.5) and 1 M ammonium sulphate gave a correspondingly great increase in binding capacity. It should be noted that potassium sulphate has a maximum solubility of about 0.6 M and therefore cannot be brought up to the required ion strength.
An increase in the ion strength with ammonium sulphate to 3.8 and 4.0 gives an additional increase in binding strength, the rule being that the lower the immunoglobulin concentration, the higher the ion strength required to maintain the binding capacity. Accordingly, there is no upper limit to the ion strength of a lyotropic salt it is desirable to use.
However, depending upon the immunoglobulin concentration in the liquid, it will always be desirable to have a minimum ion strength of 2.4, and in typical cases with in vitro cell culture supernatants, with immunoglobulin con¬ centrations between 0.01 mg/ml and 1 mg/ml, it is pre- ferred to use ion strengths of between 2.7 and 4.5. For routine use, it is preferred to use ion strengths of between 3.0 and 4.0.
The salts capable of contributing to binding immunoglobu¬ lin to thiophilic and nitrilophoric adsorption matrices belong to the group of lyotropic (water structure forming) salts. Examples of such are salts containing sulphate or phosphate ions typically with sodium, potassium or ammo- nium ions as counter ions. Furthermore, some organic ions also have lyotropic activity, e.g. the multivalent anions of organic polyvalent carboxylic acids (e.g. citrate or tartrate ions). However, it has been found according to the invention that provision of an increased binding ca- pacity by increasing the ion strength over the ion strength used in the prior art, is not limited to ammonium sulphate, but that the increased binding capacity achiev¬ able applies to all inorganic and organic salts having lyotropic properties.
The other mentioned drawback of known processes for puri¬ fying immunoglobulings by means of thiophilic or nitrilo¬ phoric adsorption matrices is that the eluted immunoglobu¬ lin (the product of the purification) is significantly contaminated by other proteins, e.g. transferrin and o-2- macroglobulin.
It has surprisingly been found that this contamination can greatly be prevented by flushing the adsorption matrix after the adsorption of the immunoglobulin with a solution of a lyotropic salt, which is present in an amount such that the ion strength in the solution is lower than the ion strength of the solution which was used for adsorbing the immunoglobulin to the adsorption matrix, and in cer- tain cases that pH is below 7.5. Hutchens and Porath, Analytical Biochemistry, vol. 159, p. 217-226, 1986 have described that binding of immunoglobu¬ lins to thiophilic adsorbents is pH dependent, but it has not previously been reported, disclosed or suggested that utilization of this pH dependency in connection with the flushing procedure after adsorption of the immunoglobulin should be able to increase the purity of the eluted immunoglobulin.
The process of the invention may e.g. be used in the puri¬ fication of immunoglobulin from monoclonal in vitro cell culture supernatants according to the following specific procedure, comprising:
admixing the cell culture supernatant with ammonium sul¬ phate and sodium acetate to a final concentration of 1.0 M and 0.05 M, respectively, pH 5.2, and then contacting the liquid with the adsorption matrix, typically by passing the liquid through a column containing it,
washing non-bound and bound contaminating proteins out of the matrix with a buffer solution consisting of 0.3 M ammonium sulphate + 0.05 M sodium acetate, pH 5.2, and
eluting the bound proteins, including immunoglobulins, with a buffer solution, which has a low salt content, e.g. 0.05 M Tris/HCl, pH 9.0.
The process of the invention may also be used for purify- ing immunoglobulins from other liquids, e.g. serum or ascites liquid, but then requires individual adjustment of the ion strength of the flushing buffer with respect to the lyotropic salt and the pH value of the flushing buffer. The result will be an increased purity of the immunoglobulin, without the binding capacity of the ad¬ sorption matrix being significantly diminished. Likewise, individual adjustment of ion strength and pH value will be desirable depending upon the type of the immunoglobulin (for murine antibodies depending upon whether IgG-, IgG2A- IgG2B, I G , IgM or IgE is involved).
The preferred ion strength of the flushing buffer depends upon the specific application and the present contamina¬ tions, but is typically between 0 and 2.25. In most cases the most preferred range is between 0.6 and 1.5. In the same manner, the preferred pH value of the flushing buffer depends upon the specific application, but is typically between pH 2.5 and pH 7.5. Owing to the stability of the immunoglobulin during the flushing procedure and the efficiency of the process, a more preferred range will be between pH 3.0 and pH 6.5, while the most preferred range will be between pH 3.5 and pH 6.0. It is particularly pre¬ ferred that pH is between 4.0 and 5.5.
The pH value of the elution buffer is preferably above 7.0, but may also be lower. Elution can also be performed by changing the dielectric!ty constant of the buffer, e.g. by addition of ethylene glycol. The selection of elution method is generally independent upon the process for bind¬ ing the immunoglobulin and subsequent washing of contami- nations.
4. EXAMPLES
Example 1
Production of 2-hυdroxypyridine derivatised divinyl sulphone activated agarose
1) Divinyl sulphone activated agarose containing about 40 micromoles of vinyl sulphone groups per ml of wet drained gel (Mini Leak High, Kem-En-Tec, Denmark) was washed on a suction filter with 2-3 volumes of ion exchanged water. The gel was drained by slight suc¬ tion, and 10 g of wet drained gel were weighed.
2) 0.5 g of 2-hydroxypyridine was dissolved in 10 ml of 0.1 M dipotassium phosphate buffer, which was titrated to pH 11.0 with sodium hydroxide. After dis¬ solution, the solution was again adjusted to pH 11.0. 2 mg of sodium boron hydride were added, and the re- suiting solution was mixed with the divinyl sulphone activated agarose. The gel was incubated with the so¬ lution for 18 hours at room temperature.
3) The gel was then washed thoroughly with 50% ethanol in water, with 25% ethanol in water and finally with pure water.
The resulting matrix contained about 40 micromoles of 2- hydroxypyrine per ml of wet drained matrix.
Example 2
Production of 4-hydroxypyridine derivatised divinyl sul¬ phone activated agarose
The procedure was the same as described in example 1, but with 4-hydroxypyridine instead of 2-hydroxypyridine.
The resulting matrix contained about 40 micromoles of 4- hydroxypyrine per ml of wet drained matrix.
Example 3
Production of 4-methoxyphenol derivatised divinyl sulphone activated agarose The procedure is the same as described in example 1, but with 4-methoxyphenol instead of 2-hydroxypyridine.
The resulting matrix contained about 40 micromoles of 4- methoxyphenol per ml of wet drained matrix.
Example 4
Production of 4-aminobenzoic acid derivatised divinyl sul- phone activated agarose
The procedure was the same as described in example 1, but with 4-aminobenzoic acid instead of 2-hydroxypyridine.
The resulting matrix contained about 40 micromoles of 4- aminobenzoic acid per ml of wet drained matrix.
Example 5
Production of phenol derivatised divinyl sulphone acti¬ vated agarose
The procedure was the same as described in example 1, but with phenol instead of 2-hydroxypyridine.
The resulting matrix contained about 40 micromoles of phe¬ nol per ml of wet drained matrix.
Example 6
Production of divinyl sulphone activated agarose coupled with various ligands
The procedure described in example 1 was used to produce divinyl sulphone activated agarose derivatized with the following ligand precursors: xanthine, 1-hydroxybenzotriazole, 2-hydroxybenzylalcohol, 2,4-dihydroxy-6-methylpyrimidine, 4-aminosalicylic acid, 2-aminothiazole, 2-aminopyridine, 2-aminopyrimidine, 2- hydroxypyrimidine, 4-hydroxypyrimidine, imidazole, 3- amino-1,2,4,-triazole, 2-hydroxybenzhydroxamic acid, and 4-chloropheno1
instead of 2-hydroxypyridine.
All compounds mentioned are commercially available.
The resulting matrices contained about 30-40 micromoles of ligands.
Example 7
Production of phenol derivatised divinyl sulphone acti¬ vated agarose with medium ligand concentration
The procedure was the same as described in example 1, but with phenol instead of 2-hydroxypyridine, using a divinyl sulphone activated agarose containing 20 micromoles of vi¬ nyl sulphone groups per ml of wet matrix (Mini Leak Medium, Kem-En-Tec).
The resulting matrix contained about 20 micromoles of phe¬ nol per ml of wet drained matrix.
Example 8
Production of phenol derivatised divinyl sulphone acti¬ vated agarose with low ligand concentration
The procedure was the same as described in example 1, but with phenol instead of 2-hydroxypyridine, using a divinyl sulphone activated agarose containing about 5 micromoles of vinyl sulphone groups per ml of wet drained matrix (Mini Leak Low, Kem-En-Tec).
The resulting matrix contained about 5 micromoles of phe- nol per ml of wet drained matrix.
Example 9
Production of known mercapto ethanol derivatised divinyl sulphone activated agarose for comparison
1) Divinyl sulphone activated agarose containing about 40 micromoles of vinyl sulphone groups per ml of wet drained gel (Mini Leak High, Kem-En-Tec, Denmark) was washed on a suction filter with 2-3 volumes of ion exchanged water. The gel was drained by slight suc¬ tion, and 10 g of wet drained gel were weighed.
2) 5% v/v mercapto ethanol in water was adjusted with sodium hydroxide to pH 9.5, and the resulting solu¬ tion was mixed with a gel.
The gel was incubated with the solution for 18 hours at room temperature.
3) The gel was then washed thoroughly with 50% ethanol in water, 25% ethanol in water and finally with pure water.
The resulting matrix contained about 40 micromoles of mer¬ capto ethanol per ml of wet drained matrix. Example 10
Prior art purification of immunoglobulins from human serum
The matrices, which were produced according to examples 1- 4 and example 8, were used for purifying immunoglobulins from human serum according to the following known process (Lihme & Heegaard, Analytical Biochemistry, vol. 192, p. 64-69, 1991):
1) 3 ml of human serum were diluted 1:1 with 1.5 M (NH4)2S04.
2) The sample was applied to a column packed with 3 g of gel (respectively 2- and 4-hydroxypyridine, 4- methoxyphenol, 4-aminobenzoic acid and mercapto ethanol derivatised divinyl sulphone activated aga¬ rose). The respective columns have been equilibrated with 0.75 M (NH.)2S04 beforehand.
3) After application of the sample the gel was washed with 0.75 M (NH.)2S0. buffer until unbound proteins were washed out of the column.
4) The bound proteins, including the immunoglobulin, were eluted with 0.1 M NaCl.
As an expression of the bound and subsequently eluted amount of protein from the individual matrices, the EU figure of the eluate was calculated by means of the following formula:
(E-_Rn of eluate) * (volume of eluate) = EU ("extinction units" ). The qualitative composition of the eluates was determined by crossed immonoelectrophoresis. The result showed that:
EU02-.hyd,roxypyri.d,m. e = 15.7 EU4.-.hyd_roxypyπ.d.ι.ne = 11.4
EU4.-met.h.oxyph.eno1. = 15.9
EU4-amm. o,benzoi.c aci.d, = 13.8
EUmercapto ethanol = 15'3
The matrices of the invention and the known matrix (mer¬ capto ethanol) thus bound comparable amounts of total protein and substantially the same amounts of immunoglobu¬ lin. None of the matrices bound albumin. The smaller amount of total protein eluted from the 4-hydroxypyridine matrix reflects a higher selectivity for immunoglobulin than the other matrices. It can therefore be concluded that the position of the substituent and on the whole the fine structure of the ligand have a decisive influence on the selectivity of the matrix.
Example 11
Known purification of proteins from human serum with phenol derivatised divinyl sulphone activated agarose matrices with different ligand concentration according to the invention
The influence of the ligand concentration on the protein fractionation was examined for the three phenol deriva- tised divinyl sulphone activated matrices, produced as described in examples 5, 7 and 8.
The raw material was human serum, and purification was performed so that the conditions during application pro- mote binding of most serum proteins, (i.e. a higher ammo¬ nium sulphate concentration was used than the one used for selective binding of immunoglobulins) .
Process
1) Human serum was diluted 1:1 with 3.0 M (NH.)-,S04 and centrifugated 30 minutes at 4000 rpm. The precipitate was discarded, while the supernatant was used for purification.
2) 1 ml of supernatant was then applied to 3 columns packed with 10 ml of phenol derivatised agarose con¬ taining about 40, about 20 and about 5 micromoles of phenol per ml of matrix (from examples 5, 7 and 8), respectively.
3) After application of the sample, the columns were flushed with 0.01 M K2HP04, 1.5 M (NH4)-,S04 buffer pH 7.2.
4) The matrices were eluted with a gradient from 0.01 M K2HP04, 1.5 M (NH4)2S04 pH 7.2 to 0.01 M K2HP04, 0.25 M NaCl pH 7.2.
The eluates were collected in fractions and analyzed by fused rocket immunoelectrophoresis for qualitative deter¬ mination of the protein content.
The results showed that the adsorption matrix with the highest content of phenyl groups (40 micromoles/ml) bound the proteins most strongly, i.e. the proteins were gene¬ rally eluted at a lower ion strength compared with the two other adsorption matrices. Furthermore, this matrix also bound the proteins more strongly than known thiophilic matrices, such as the mercapto ethanol derivative, the immunoglobulin G bound so strongly that it could only be liberated by a subsequent elution with 40% ethylene gly- col. However, the thiophilic nature showed itself clearly in that albumin bound much more weakly to the matrix than immunoglobulin and much more weakly than the known hydro- phobic matrices, such as octyl-Sepharose.
The adsorption matrix, with a content of about 20 micro¬ moles of phenyl groups per ml of wet gel, exhibited a binding pattern which corresponds closely to the pattern achieved with known thiophilic matrices with a higher ligand concentration (about 40-60 micromoles/ml).
The adsorption matrix, with a content of about 5 micro¬ moles of phenyl groups per ml, bound the proteins rather weakly, but still exhibited preference to binding of immunoglobulins.
All matrices bound immunoglobulin more strongly than albumin.
Example 12
Binding capacity for immunoglobulin from in vitro cell culture supernatant - comparison of processes
Process I (according to prior art)
1) 300 ml of in vitro hybridoma cell culture supernatant containing 50 j_g of murine monoclonal immunoglobulin G- per ml and 10% v/v foetal calf serum are admixed with potassium sulphate and tris-hydroxymethyl amino- metha__e (Tris) to a final concentration of 0.5 M and 0.1 M, respectively, with pH adjusted with hydro¬ chloric acid to 7.6.
2) The supernatant is passed through a column packed with 5 ml of 2-hydroxypyridine derivatised divinyl sulphone activated agarose, as produced in example 1. The effluent from the column is collected in fractions, which are analyzed for their content of murine immunoglobulin by immunodiffusion.
Process II (according to the invention)
The test is performed like process I, but the potassium sulphate added in item 1 is replaced by 0.8 M ammonium sulphate, pH being kept constant at 7.6.
Process III
The test is performed like process II, the ammonium sul- phate concentration being merely increased to 1.0 M.
Process IV
The test is performed like process II, the ammonium sul- phate concentration being merely increased to 1.2 M.
The results are expressed as number of ml cell culture supernatant passing the column with the adsorption matrix before the effluent concentration of murine immunoglobulin is 50% of the start concentration (defined as "50% satura¬ tion" ).
Table I
"50% saturation" ml
Process I 20
Process II 30
Process III 250 Process IV >300
As will be seen from table I, increase in the ion strength of the medium results in a strong increase of the binding capacity for murine immunoglobulin.
Example 13
The test described in example 12 was repeated, the adsorp¬ tion matrix being merely replaced by the mercapto ethanol derivative which was produced according to example 9.
Table I
"50% saturation" ml
Process I 15
Process II 20 Process III 230
Process IV >300
As will be seen, an increase in the ion strength also has a strong positive effect on the binding capacity of known thiophilic adsorption matrices. Example 14
The test described in example 12 was repeated, the ammo¬ nium sulphate being merely replaced by sodium sulphate.
Table I
"50% saturation" ml
Process I 30
Process II 40
Process III >300 Process IV >300
As will be seen, an increase in the ion strength also has a strong positive effect on the binding capacity when us¬ ing sodium sulphate instead of ammonium sulphate.
Example 15
Purity of immunoglobulin isolated from in vitro cell cul¬ ture supernatant - comparison of processes
Process I ( nown washing)
1) 300 ml of in vitro hybridoma cell culture supernatant containing 50 ng of murine monoclonal immunoglobulin G- per ml and 10% v/v foetal calf serum were admixed with ammonium sulphate and tris-hydroxymethyl amino- methane (Tris) to a final concentration of 1.0 M and 0.1 M, respectively, pH being adjusted with hydro¬ chloric acid to 7.6. 2) The supernatant was passed through a column packed with 5 ml of 2-hydroxypyridine derivatised divinyl sulphone activated agarose, as produced according to example 1.
3) The column was washed with about 50 ml of 1.0 M ammonium sulphate + 0.01 M Tris/HCl, pH 7.6.
4) Bound proteins were released and eluted with 0.05 M Tris/HCl, pH 9.0.
The eluate was collected in one fraction and analyzed for purity by means of sodiumdodecyl polyacrylamide electrophoresis followed by electronic scanning. The yield in mg of murine immunoglobulin G. is determined by quantitative rocket immunoelectrophoresis. The purity is the immunoglobulin in % of the total amount of protein in the sample.
Process II
The test was performed like process I, the washing buffer in item 3 being merely replaced by 0.3 M ammonium sulphate + 0.05 M sodium acetate, pH 5.2.
Process III
The test was performed like process I, the washing buffer in item 3 being merely replaced by 0.3 M ammonium sulphate + 0.1 M Tris/HCl, pH 7.6. Yield, mg Purity, %
Process I 11.5 about 30 Process II 11.0 90 Process III <0.5 95
It will be seen from the results that a reduction in ion strength as well as pH in the flushing buffer increases the purity of the eluted immunoglobulin while retaining the high capacity. If pH is not reduced simultaneously with the ion strengh, a high purity is obtained, but the yield is very small.
Example 16
A comparative test of the process was performed like in example 15, the adsorption matrix being merely replaced by the mercapto ethanol derivative which was produced accord¬ ing to example 9.
The result corresponded completely to the result in example 15, which shows that the process of the invention also increases the purity of the eluted IgG for known thiophilic matrices.

Claims

P a t e n t C l a i m s :
1. A thiophilic adsorption matrix comprising a hydro- philic polymer network to which divinyl sulphone groups are bound via an ether oxygen atom, a thioether sulphur atom or a nitrogen atom, and the divinyl sulphone groups are moreover covalently bound to a ligand, c h a r a c t e r i z e d in that the ligand is a group of the general formula X-R, wherein X is NQ, wherein N is nitrogen, Q is H(CH -__>)II and n = 0,1,2 or 3, or 0 (oxygen), and wherein R is an aromatic or heteroaromatic ring system which is optionally substituted, consisting of one or more rings, and R does not comprise nitrile groups.
2. A thiophilic adsorption matrix according to claim 1, c h a r a c t e r i z e d in that R is substituted with substituents selected from:
alkyl, such as methyl, ethyl, propyl and butyl; alkoxy, such as methoxy, ethoxy, propyloxy, butyloxy; carboxyl, such as -(CH -9C-i)IICOOH, n = 0,1,2,3; carboxamide, such as -(CH ) C0NH , n = 0,1,2,3; carboxyhydroxyamide, such as -(CH9) CONHOH, n = 0,1,2,3; halogen, such as -F, -Cl, -Br and -I; nitro, -N02; sulphonic acid, -SO^H; hydroxy1, -OH; alcohols, such as -(CH ) OH, n = 1,2,3; amines, such as -(CH ) NH , n = 1,2,3.
3. A thiophilic adsorption matrix according to claims 1 and 2, c h a r a c t e r i z e d in that the ligand is coupled by reacting a ligand precursor selected from the group consisting of 2-hydroxypyridine, 4-hydroxypyridine, xanthine, 4-methoxyphenol, 1-hydroxybenzotriazole, 4- aminobenzoic acid, 2-hydroxybenzylalcohol, 2,4-dihydroxy- 6-methylpyrimidine, 4-aminosalicylic acid, 2-amino- thiazole, 2-aminopyridine, 2-aminopyrimidine, 2-hydroxy- pyrimidine, 4-hydroxypyrimidine, imidazole, 3-amino-l,2,4- triazole, 4-hydroxybenzoic acid butyl amide, 2-hydroxy¬ benzhydroxamic acid, phenol and 4-chlorophenol with the divinyl sulphone groups of the hydrophilic polymer network.
4. A thiophilic adsorption matrix according to claims 1-
3, c h a r a c t e r i z e d in that the ligand concen¬ tration is between 5 and 80 micromoles per ml of wet ma¬ trix, preferably between 5 and 40 micromoles per ml, in particular between 10 and 40 micromoles per ml of wet matrix.
5. A thiophilic adsorption matrix according to claims 1-
4, c h a r a c t e r i z e d in that the polymeric net¬ work is selected from: polysaccharides, preferably agar, agarose, dextran, starch and cellulose, in particular agarose, and synthetic organic polymers, preferably poly- acrylamide, polyamide, polyimide, polyester, polyether, polymeric vinyl compounds and substituted derivatives thereof either as particles, membranes or contained in membranes.
6. A process for producing a thiophilic adsorption matrix comprising a hydrophilic polymer network t© which divinyl sulphone groups are bound via an ether oxygen atom, a thioether sulphur atom or a nitrogen atom, and the divinyl sulphone groups are moreover covalently bound to a ligand, said ligand being a group of the general formula X-R, wherein X is NQ, wherein N is nitrogen and Q is H(CH -C-)II and n = 0,1,2 or 3 or 0 (oxygen), and wherein R is an aromatic or heteroaromatic ring system which is optionally substituted, consisting of one or more rings, and R does not comprise nitrile groups, wherein the polymer network is activated by contacting it with divinyl sulphone, and then the activated polymer network is reacted with a ligand precursor.
7. A process according to claim 6, c h a r a c t e r ¬ i z e d in that the ligand precursor is selected from the following substances: 2-hydroxypyridine, 4-hydroxypyri¬ dine, xanthine, 4-methoxyphenol, 1-hydroxybenzotriazole, 4-aminobenzoic acid, 2-hydroxybenzylalcohol, 2,4-di- hydroxy-6-methylpyrimidine, p-aminosalicylic acid, 2- aminothiazole, 2-aminopyridine, 2-aminopyrimidine, 2- hydroxypyrimi ine, 4-hydroxypyrimidine, imidazole, 3- amino-l,2,4-triazole, 4-hydroxybenzoic acid butyl amide, 2-hydroxybenzhydroxamic acid, phenol and 4-chlorophenol.
8. A process for purifying protein from a liquid, wherein the liquid is contacted with a thiophilic adsorption ma¬ trix, and the protein is then processed from either the thiophilic adsorption matrix or from the liquid, c h a ¬ r a c t e r i z e d in that the thiophilic adsorption matrix comprises a hydrophilic polymer network to which divinyl sulphone groups are bound via an ether oxygen atom, a thioether sulphur atom or a nitrogen atom, and the divinyl sulphone groups are moreover covalently bound to a ligand, said ligand being a group of the general formula X-R, wherein X is NQ, wherein N is nitrogen and Q is H(CH -__t)II and n = 0-3, or 0 (oxygen), and wherein R is an aromatic or heteroaromatic ring system, which is optionally substituted, consisting of one or more rings, and R does not comprise nitrile groups.
9. A process according to claim 8, c h a r a c t e r ¬ i z e in that R is substituted with substituents selected from: alkyl, such as methyl, ethyl, propyl and butyl; alkoxy, such as methoxy, ethoxy, propyloxy, butyloxy; carboxyl, such as -(CH2)nC00H, n = 0,1,2,3; carboxamide, such as -(CH9) C0NH9, n = 0,1,2,3; carboxyhydroxyamide, such as -(CH -u)IICONHOH, n = 0,1,2,3; halogen, such as -F, -Cl, -Pr __Λd -I; nitro, -N09; sulphonic acid, -S0-.H; hydroxyl, -OH; alcohols, such as -(CH2) OH, n = 1,2,3; amines, such as -(CH9) NH , n = 1,2,3.
10. A process according to claims 8-9, c h a r a c ¬ t e r i z e d in that the ligand is coupled by reacting a ligand precursor selected from the group consisting of 2- hydroxypyridine, 4-hydroxypyridine, xanthine, 4-methoxy- phenol, 1-hydroxybenzotriazole, 4-aminobenzoic acid, 2- hydroxybenzyl alcohol, 2,4-dihydroxy-6-methylpyrimidine, 4-aminosalicylic acid, 2-aminothiazole, 2-aminopyridine, 2-aminopyrimidine, 2-hydroxypyrimidine, 4-hydroxypyrimi- dine, imidazole, 3-amino-l,2,4-triazole, 4-hydroxybenzoic acid butyl amide, 2-hydroxybenzoinhydroxamic acid, phenol or 4-chlorophenol with the divinyl sulphone groups of the hydrophilic polymer network.
11. A process for purifying immunoglobulin from a liquid, comprising adding a lyotropic buffer to the liquid, con¬ tacting the liquid with a thiophilic adsorption matrix, washing the thiophilic adsorption matrix with a lyotropic buffer solution, and then eluting the washed thiophilic adsorption matrix with an elution liquid, c h a r a c ¬ t e r i z e d in that the lyotropic buffer in the liquid has an ion strength above 2.25, preferably between 2.25 and 4.5, in particular between 3.0 and 4.0.
12. A process for purifying immunoglobulin from a liquid, comprising adding a lyotropic buffer to the liquid, con¬ tacting the liquid with a thiophilic adsorption matrix, washing the thiophilic adsorption matrix with a lyotropic buffer solution, and then eluting the washed thiophilic adsorption matrix with an elution liquid, c h a r a c ¬ t e r i z e d in that the lyotropic buffer solution has an ion strength below 2.25, preferably between 0 and 2.25, in particular between 0.6 and 1.5.
13. A process according to claim 12, c h a r a c t e r ¬ i z e in that pH of the lyotropic buffer solution is below 7.5, preferably between 2.5 and 7.5, in particular between 3.0 and 6.0, especially preferred being the range 3.5 to 6.0, in particular 4.0 to 5.5.
14. A process according to claims 12-13, c h a r a c ¬ t e r i z e d in that the lyotropic buffer in the liquid has an ion strength above 2.25, preferably between 2.25 and 4.5, in particular between 3.0 and 4.0.
15. A process according to claims 11-14, c h a r a c ¬ t e r i z e d in that the thiophilic adsorption matrix is selected from divinyl sulphone activated polymer network to which divinyl sulphone groups are bound via an ether oxygen atom, a thioether sulphur atom or a nitrogen atom, and the divinyl sulphone groups are moreover covalently bound to a ligand, which is selected from:
a) an alkyl, aryl or heteroaromatic group, which is op¬ tionally substituted and which is bound to a divinyl sulphone group via a sulphur atom,
b) an aromatic or heteroaromatic ring system, which is optionally substituted, consisting of one or more rings whose substituents do not comprise nitrile groups, and which is bound to a divinyl sulphone via an oxygen atom or a nitrogen atom,
c) an aliphatic or a heterocyclic ring system having at least one nitrogen atom in the ring with one or more side groups consisting of or comprising nitrile groups bound to a divinyl sulphone group via a sul¬ phur atom, an oxygen atom or a nitrogen atom.
16. A process according to claim 15, c h a r a c t e r ¬ i z e d in that the polymeric network is selected from polysaccharides, preferably agar, agarose, dextran, starch and cellulose, in particular agarose, and synthetic orga¬ nic polymers, preferably polyacrylamide, polyamide, poly- imide, polyester, polyether, polymeric vinyl compounds and substituted derivatives thereof either as particles, mem¬ branes or contained in membranes.
17. A process according to claims 11-16, c h a r a c - t e r i z e d in that the lyotropic buffer and the lyo¬ tropic buffer solution comprise lyotropic salts selected from sodium sulphate, potassium sulphate, ammonium sul¬ phate, sodium phosphate, potassium phosphate and ammonium phosphate, or organic salts of polyvalent carboxylic acids, such as sodium citrate, sodium tartrate, potassium citrate, potassium tartrate, or mixtures thereof.
18. A process according to claims 11-16, c h a r a c ¬ t e r i z e d in that the liquid is a biological liquid, preferably blood, serum, ascites liquid or cell culture supernatant, in particular cell culture supernatant.
PCT/DK1992/000092 1991-03-22 1992-03-20 Adsorption matrices WO1992016292A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP92907410A EP0639111A1 (en) 1991-03-22 1992-03-20 Adsorption matrices
AU14688/92A AU663700B2 (en) 1991-03-22 1992-03-20 Adsorption matrices
JP4507119A JPH06508058A (en) 1991-03-22 1992-03-20 adsorption matrix

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0527/91 1991-03-22
DK91527A DK52791D0 (en) 1991-03-22 1991-03-22 ADSORPTION MATRIX

Publications (1)

Publication Number Publication Date
WO1992016292A1 true WO1992016292A1 (en) 1992-10-01

Family

ID=8094556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1992/000092 WO1992016292A1 (en) 1991-03-22 1992-03-20 Adsorption matrices

Country Status (5)

Country Link
EP (1) EP0639111A1 (en)
JP (1) JPH06508058A (en)
AU (1) AU663700B2 (en)
DK (1) DK52791D0 (en)
WO (1) WO1992016292A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013312A1 (en) * 1993-11-12 1995-05-18 Shearwater Polymers, Inc. Water soluble active sulfones of poly(ethylene glycol)
WO1995033557A1 (en) * 1994-06-07 1995-12-14 Sven Oscarsson Alkali resistant protein adsorbent
WO1997047383A1 (en) * 1996-06-10 1997-12-18 Dianova Lizenz- Und Beteiligungsgesellschaft Mbh Conjugate useful for binding substances
WO1998008603A1 (en) * 1996-08-30 1998-03-05 Upfront Chromatography A/S Isolation of immunoglobulins
WO1998051672A2 (en) * 1997-08-12 1998-11-19 Oy Juvantia Pharma Ltd. A method for the preparation of tertiary amines, a compound useful therefor and alpha-2-receptor active tetrahydroisoquinoline derivatives
WO1999007751A1 (en) * 1997-08-05 1999-02-18 Akzo Nobel N.V. Vinyl sulphone modified polymer
WO2003070944A1 (en) * 2002-02-21 2003-08-28 Amersham Biosciences Ab Method of separation using aromatic thioether ligands
WO2005073711A2 (en) * 2004-01-20 2005-08-11 Pall Corporation Chromatographic material for the absorption of proteins at physiological ionic strength
WO2005121163A2 (en) 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
US7144743B2 (en) 2002-09-13 2006-12-05 Pall Corporation Preparation and use of mixed mode solid substrates for chromatography adsorbents and biochip arrays
US7812138B2 (en) 2001-06-01 2010-10-12 Upfront Chromatography A/S Fractionation of protein containing mixtures

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5498025B2 (en) * 2008-03-13 2014-05-21 公益財団法人相模中央化学研究所 Novel thiazole derivative-immobilized matrix and production method thereof
WO2009113637A1 (en) * 2008-03-12 2009-09-17 東ソー株式会社 Novel thiazole derivative, matrix having thiazole derivative immobilized thereon, method for production of the thiazole derivative, and method for production of the matrix
JP5455380B2 (en) * 2008-03-12 2014-03-26 公益財団法人相模中央化学研究所 Novel thiazole derivative and method for producing the same
JP2014507649A (en) * 2011-01-18 2014-03-27 バクスター・インターナショナル・インコーポレイテッド Measurement of anti-β-amyloid antibody in human blood
JP5889590B2 (en) * 2011-10-05 2016-03-22 東ソー株式会社 Adsorbents for protein analysis, separation and purification

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420733B (en) * 1974-05-30 1981-10-26 Exploaterings Ab Tbf GEL PRODUCT, INCLUDING THIOSULPHATE GROUPS AND SETS FOR PREPARING THEREOF
EP0165912A2 (en) * 1984-05-17 1985-12-27 Jerker Porath Thioether adsorbent intended for the separation of proteins and the like
SE461505B (en) * 1981-02-10 1990-02-26 Tanabe Seiyaku Co ADSORBENT CONSISTING OF A WATER-INSULATIVE CARRIER CONNECTED TO A HETEROCYCLIC COMPOUND WITH A DISTANCE SUBSTANCE AND ITS APPLICATION TO DISPOSE PYROGENS FROM A PYROGEN CONTAINING SOLUTION
SE462165B (en) * 1988-02-26 1990-05-14 Porath Jerker MAKE SURE TO ADORABLE A COMPARATIVE PROTEIN COMPLEX, SPECIFIC SIGNIFICANT BY BIOSPECIFIC DETERMINATION METHODS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420733B (en) * 1974-05-30 1981-10-26 Exploaterings Ab Tbf GEL PRODUCT, INCLUDING THIOSULPHATE GROUPS AND SETS FOR PREPARING THEREOF
SE461505B (en) * 1981-02-10 1990-02-26 Tanabe Seiyaku Co ADSORBENT CONSISTING OF A WATER-INSULATIVE CARRIER CONNECTED TO A HETEROCYCLIC COMPOUND WITH A DISTANCE SUBSTANCE AND ITS APPLICATION TO DISPOSE PYROGENS FROM A PYROGEN CONTAINING SOLUTION
EP0165912A2 (en) * 1984-05-17 1985-12-27 Jerker Porath Thioether adsorbent intended for the separation of proteins and the like
SE462165B (en) * 1988-02-26 1990-05-14 Porath Jerker MAKE SURE TO ADORABLE A COMPARATIVE PROTEIN COMPLEX, SPECIFIC SIGNIFICANT BY BIOSPECIFIC DETERMINATION METHODS

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1085689C (en) * 1993-11-12 2002-05-29 舍沃特聚合物公司 Water soluble active sulfones of poly (ethylene glycol) and relative polymer for modifying surface and molecule of substances
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU687937B2 (en) * 1993-11-12 1998-03-05 Nektar Therapeutics Water soluble active sulfones of poly(ethylene glycol)
WO1995013312A1 (en) * 1993-11-12 1995-05-18 Shearwater Polymers, Inc. Water soluble active sulfones of poly(ethylene glycol)
US5739208A (en) * 1993-11-12 1998-04-14 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US7214366B2 (en) 1993-11-12 2007-05-08 Nektar Therapeutics Al, Corporation Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6894025B2 (en) 1993-11-12 2005-05-17 Nektar Therapeutics Al, Corp. Biologically active molecules having thiol moiety conjugated to polymers containing ethyl sulfone moiety
EP1176160A3 (en) * 1993-11-12 2004-03-03 Shearwater Polymers, Inc. Water soluble active sulfones of poly(ethylene glycol)
US5900461A (en) * 1993-11-12 1999-05-04 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1995033557A1 (en) * 1994-06-07 1995-12-14 Sven Oscarsson Alkali resistant protein adsorbent
US5942463A (en) * 1994-06-07 1999-08-24 Oscarsson; Sven Alkali resistant protein adsorbent
WO1997047383A1 (en) * 1996-06-10 1997-12-18 Dianova Lizenz- Und Beteiligungsgesellschaft Mbh Conjugate useful for binding substances
US7442779B2 (en) 1996-08-30 2008-10-28 Upfront Chromatography A/S Isolation of proteins
AU729039C (en) * 1996-08-30 2001-08-02 Upfront Chromatography A/S Isolation of immunoglobulins
AU729039B2 (en) * 1996-08-30 2001-01-25 Upfront Chromatography A/S Isolation of immunoglobulins
US6498236B1 (en) 1996-08-30 2002-12-24 Upfront Chromatography A/S Isolation of immunoglobulins
US7745582B2 (en) 1996-08-30 2010-06-29 Upfront Chromatography Isolation of immunoglobulins
EP1386660A1 (en) * 1996-08-30 2004-02-04 Upfront Chromatography A/S Isolation of proteins
EP2095873A1 (en) 1996-08-30 2009-09-02 Upfront Chromatography A/S Isolation of immunoglobulins
US6919436B2 (en) 1996-08-30 2005-07-19 Upfront Chromatography A/S Isolation of proteins
WO1998008603A1 (en) * 1996-08-30 1998-03-05 Upfront Chromatography A/S Isolation of immunoglobulins
WO1999007751A1 (en) * 1997-08-05 1999-02-18 Akzo Nobel N.V. Vinyl sulphone modified polymer
WO1998051672A2 (en) * 1997-08-12 1998-11-19 Oy Juvantia Pharma Ltd. A method for the preparation of tertiary amines, a compound useful therefor and alpha-2-receptor active tetrahydroisoquinoline derivatives
WO1998051672A3 (en) * 1997-08-12 1999-03-11 Juvantia Pharma Ltd Oy A method for the preparation of tertiary amines, a compound useful therefor and alpha-2-receptor active tetrahydroisoquinoline derivatives
US7812138B2 (en) 2001-06-01 2010-10-12 Upfront Chromatography A/S Fractionation of protein containing mixtures
US7956166B2 (en) 2001-06-01 2011-06-07 Upfront Chromatography A/S Fractionation of protein containing mixtures
EP2272378A1 (en) 2001-06-01 2011-01-12 Upfront Chromatography A/S Fractionation of protein containing mixtures
US7659392B2 (en) * 2002-02-21 2010-02-09 Ge Healthcare Bio-Sciences Ab Method of separation using aromatic thioether ligands
WO2003070944A1 (en) * 2002-02-21 2003-08-28 Amersham Biosciences Ab Method of separation using aromatic thioether ligands
US7144743B2 (en) 2002-09-13 2006-12-05 Pall Corporation Preparation and use of mixed mode solid substrates for chromatography adsorbents and biochip arrays
US7326776B2 (en) 2002-09-13 2008-02-05 Pall Corporation Preparation and use of mixed mode solid substrates for chromatography adsorbents and biochip arrays
WO2005073711A2 (en) * 2004-01-20 2005-08-11 Pall Corporation Chromatographic material for the absorption of proteins at physiological ionic strength
WO2005073711A3 (en) * 2004-01-20 2005-11-10 Pall Corp Chromatographic material for the absorption of proteins at physiological ionic strength
US8021889B2 (en) 2004-01-20 2011-09-20 Pall Corporation Chromatographic material for the absorption of proteins at physiological ionic strength
WO2005121163A2 (en) 2004-06-07 2005-12-22 Upfront Chromatography A/S Isolation of plasma or serum proteins
EP2277912A2 (en) 2004-06-07 2011-01-26 Upfront Chromatography A/S Isolation of plasma or serum proteins
US9428545B2 (en) 2004-06-07 2016-08-30 Therapure Biopharma Inc. Process for isolation of plasma or serum proteins
EP3127916A1 (en) 2004-06-07 2017-02-08 Therapure Biopharma Inc. Isolation of plasma or serum proteins
US9624260B2 (en) 2004-06-07 2017-04-18 Therapure Biopharma Inc. Process for isolation of plasma or serum proteins

Also Published As

Publication number Publication date
AU663700B2 (en) 1995-10-19
AU1468892A (en) 1992-10-21
JPH06508058A (en) 1994-09-14
EP0639111A1 (en) 1995-02-22
DK52791D0 (en) 1991-03-22

Similar Documents

Publication Publication Date Title
WO1992016292A1 (en) Adsorption matrices
US5092992A (en) Polyethyleneimine matrixes for affinity chromatography
US5719269A (en) Chromatography adsorbents utilizing mercapto heterocyclic ligands
Chaga Twenty-five years of immobilized metal ion affinity chromatography: past, present and future
US5047513A (en) Metal chelate resins
US5085779A (en) Polyethyleneimine matrixes for affinity chromatography
JPH09501719A (en) Heparin functional affinity support
Harakas Biospecific affinity chromatography
JPH0427504B2 (en)
EP0491688B1 (en) Methods for activating polymeric carriers and compositions prepared therefrom for use in affinity chromatography
JPH01229965A (en) Carrier for affinity chromatography with immobilized antibodies
JPS6036498A (en) Dissolution of peptides and proteins, solution thereby and use
SU1600633A3 (en) Method of purifying protein toxin of bordetella petrusis bacteria
Ostrove et al. [30] Affinity chromatography: Specialized techniques
CA1332598C (en) Polyethyleneimine matrixes for affinity chromatography
US3959249A (en) Method for isolating transferrines from biological materials
US6555661B1 (en) Simple, environmentally benign, method for purifying protein A
JPH0466559B2 (en)
US6136925A (en) Hydroxyl group-containing covalently bound polymer separating materials and processes for their preparation
Bresolin et al. Evaluation of Iminodiacetic Acid (IDA) as an Ionogenic Group for Adsorption of IgG 1 Monoclonal Antibodies by Membrane Chromatography
SU551339A1 (en) The method of purification of enzyme preparations
DK171394B1 (en) Support or carrier in solid phase, immobilized enzyme in solid phase on such a support, ligand-linked chromatography affinity matrix and method for separating or removing a substance from solution using the support
JPS60169427A (en) Method of separation of protein
CA1065305A (en) PROCESS FOR THE ENRICHMENT OF THE PREGNANCY-SPECIFIC .beta.1-GLYCOPROTEIN
KR950004134B1 (en) Polyethyleneimine matrixs fof affinity chromatography

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992907410

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: US

Ref document number: 1994 117192

Date of ref document: 19940525

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1992907410

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992907410

Country of ref document: EP